CareDx Inc Earnings Call Highlights Growth And Risks
TipRanks (Thu, 13-Aug 8:19 PM ET)
CareDx’s New Executive Advisor Receives 15,822 RSU Award—What This Could Mean for Stakeholders
Market Chameleon (Mon, 3-Aug 7:45 AM ET)
CareDx Grants Nearly 16,000 RSUs to Executive Advisor as Part of Strategic Leadership Expansion
Market Chameleon (Mon, 3-Aug 4:38 AM ET)
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 31-Jul 6:45 PM ET)
CareDx Announces Second Quarter 2026 Financial Results
Business Wire (Thu, 30-Jul 4:01 PM ET)
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
Business Wire (Thu, 16-Jul 8:35 AM ET)
Business Wire (Thu, 16-Jul 8:30 AM ET)
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
Business Wire (Wed, 1-Jul 4:05 PM ET)
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
Business Wire (Tue, 30-Jun 4:05 PM ET)
Business Wire (Thu, 18-Jun 7:05 AM ET)
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Caredx trades on the NASDAQ stock market under the symbol CDNA.
As of August 18, 2026, CDNA stock price declined to $46.18 with 814,372 million shares trading.
CDNA has a beta of 0.49, meaning it tends to be less sensitive to market movements. CDNA has a correlation of 0.01 to the broad based SPY ETF.
CDNA has a market cap of $2.39 billion. This is considered a Mid Cap stock.
Last quarter Caredx reported $132 million in Revenue and $.37 earnings per share. This beat revenue expectation by $18 million and exceeded earnings estimates by $.17.
In the last 3 years, CDNA traded as high as $49.76 and as low as $4.80.
The top ETF exchange traded funds that CDNA belongs to (by Net Assets): ARKG, VTI, IWM, XBI, VXF.
CDNA has outperformed the market in the last year with a return of +290.0%, while the SPY ETF gained +20.4%. In the last 3 month period, CDNA beat the market returning +131.2%, while SPY returned +4.1%. However, in the most recent 2 weeks CDNA has underperformed the stock market by returning -3.5%, while SPY returned +1.3%.
CDNA support price is $44.63 and resistance is $48.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDNA shares will trade within this expected range on the day.
